IceCure Medical Ltd.ICCM
Price (close)
$1.73
Market cap
$8.0M
P/E
—
Revenue (FY)
$3.4M
Net income
-$15.1M
Dividend yield
—
1-year total return
-94.4%
Net margin
-445.6%
Revenue growth
2.7%
Debt / equity
0.00x
What IceCure Medical Ltd. does.
medical device company focusing on the research and development of cryoablation systems, disposables based on LN2 for treating tumors.
Cryoablation is the process by which benign and malignant tumors, nerves or other tissues are ablated (destroyed) through freezing such
tumors while in a patient’s body. Our proprietary cryoablation technology is a minimally invasive alternative to surgical intervention,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.9M | $4.1M | $3.1M | $3.2M | $3.3M | $3.4M |
| Net income | -$3.7M | -$9.9M | -$17.0M | -$14.7M | -$15.3M | -$15.1M |
| Free cash flow | -$3.9M | -$13.1M | -$15.2M | -$13.0M | -$12.6M | -$14.6M |
More on ICCM.
- IceCure Medical Ltd. summary
- IceCure Medical Ltd. financial statements
- IceCure Medical Ltd. key metrics
- IceCure Medical Ltd. health scores and style box
- IceCure Medical Ltd. earnings
- IceCure Medical Ltd. dividends
- IceCure Medical Ltd. valuation
- IceCure Medical Ltd. ownership and insiders
- IceCure Medical Ltd. peers
Figures from IceCure Medical Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.